These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 27651406)

  • 1. Polycythaemia: an unusual presentation of multiple myeloma.
    Hutchison EJ; Taverna JA; Yu Q; Yeager AM
    BMJ Case Rep; 2016 Sep; 2016():. PubMed ID: 27651406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment with bortezomib and dexamethasone for proliferative glomerulonephritis with monoclonal IgG deposits in multiple myeloma: a case report.
    Noto R; Kamiura N; Ono Y; Tabata S; Hara S; Yokoi H; Yoshimoto A; Yanagita M
    BMC Nephrol; 2017 Apr; 18(1):127. PubMed ID: 28385149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real world experience of bortezomib re-treatment for patients with multiple myeloma at first relapse.
    Reyal Y; Popat R; Cheesman S; Rismani A; D'Sa S; Rabin N; Yong K
    Br J Haematol; 2017 May; 177(3):495-497. PubMed ID: 27062387
    [No Abstract]   [Full Text] [Related]  

  • 4. [Cellulitis due to Achromobacter xylosoxidans during bortezomib therapy for multiple myeloma].
    Kikuchi T; Mori T; Kohashi S; Yamane Y; Okayama M; Mashima E; Murakami K; Shimizu T; Kurihara Y; Ueda T; Suzuki T; Okamoto S
    Rinsho Ketsueki; 2016 Feb; 57(2):175-9. PubMed ID: 26935636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib: Potential Key Role in the Treatment of Multiple Myeloma-Related Acquired Hemophilia A.
    Brás GP; Pinto RJ; Carvalho MM; Fernandes SP; Andrade JJ; Guimarães JE
    Semin Thromb Hemost; 2017 Feb; 43(1):109-112. PubMed ID: 27992938
    [No Abstract]   [Full Text] [Related]  

  • 6. A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus - clinical significance and possible mechanisms: a case report.
    Takemori N; Imai G; Hoshino K; Ooi A; Kojima M
    J Med Case Rep; 2018 Feb; 12(1):40. PubMed ID: 29454372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse.
    Cohen OC; Counsell N; Rabin N; Popat R; Owen RG; Popova B; Schofield O; Clifton-Hadley L; Lyons-Lewis J; Rawstron A; Spence C; de Tute RM; Hughes D; Moore S; Smith P; Yong KL
    Br J Haematol; 2019 Jun; 185(5):948-951. PubMed ID: 30460696
    [No Abstract]   [Full Text] [Related]  

  • 8. Bortezomib improves survival in rare myeloma.
    Brower V
    Lancet Oncol; 2016 Jun; 17(6):e227. PubMed ID: 27160479
    [No Abstract]   [Full Text] [Related]  

  • 9. The impact of the introduction of bortezomib on dialysis independence in multiple myeloma patients with renal impairment: a nationwide Dutch population-based study.
    Oortgiesen BE; Azad R; Hemmelder MH; Kibbelaar RE; Veeger NJGM; de Vries JC; van Roon EN; Hoogendoorn M
    Haematologica; 2018 Jul; 103(7):e311-e314. PubMed ID: 29545339
    [No Abstract]   [Full Text] [Related]  

  • 10. Resolution of bilateral cystoid macular edema and subfoveal serous retinal detachments after treatment with bortezomib in a patient with "smoldering" multiple myeloma.
    Grannis CH; Dewan VN; Wang RC
    Retin Cases Brief Rep; 2014; 8(4):348-51. PubMed ID: 25372546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subepidermal bullous dermatosis associated with IgA multiple myeloma: a case report.
    Zhou Q; Jiang H; Zhu K; Han R; Cheng H
    Am J Dermatopathol; 2013 May; 35(3):e49-52. PubMed ID: 23291580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of eosinophilic dermatosis of hematologic malignancy in a patient with multiple myeloma.
    Two AM; Li C; Hata T
    Dermatol Online J; 2014 Jan; 20(1):21256. PubMed ID: 24456959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two Secondary Primary Malignancies after Bortezomib Therapy for Multiple Myeloma: A Single-center Experience.
    Guo TJ; Huang XJ; Wen L; Lu J
    Chin Med J (Engl); 2017 Jan; 130(2):239-241. PubMed ID: 28091419
    [No Abstract]   [Full Text] [Related]  

  • 14. Paraneoplastic hyperamylasaemia in association with multiple myeloma.
    Calvo-Villas JM; Alvarez I; Carretera E; Espinosa J; Sicilia F
    Acta Haematol; 2007; 117(4):242-5. PubMed ID: 17377372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of peripheral nerve microvasculitis associated with multiple myeloma and bortezomib treatment.
    Mauermann ML; Blumenreich MS; Dispenzieri A; Staff NP
    Muscle Nerve; 2012 Dec; 46(6):970-7. PubMed ID: 23225391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study.
    Sezer O; Beksac M; Hajek R; Sucak G; Cagirgan S; Linkesch W; Meltem Akay O; Gülbas Z; Nahi H; Plesner T; Snowden JA; Timurağaoğlu A; Dechow T; Lang A; Tuğlular T; Drach J; Armbrecht G; Potamianou A; Couturier C; Olie RA; Feys C; Allietta N; Terpos E
    Br J Haematol; 2017 Jul; 178(1):61-71. PubMed ID: 28382618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma.
    Hashimoto S; Kuroha T; Yano T; Sato N; Furukawa T
    Intern Med; 2016; 55(20):3025-3028. PubMed ID: 27746443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?
    Marchica V; Accardi F; Storti P; Mancini C; Martella E; Dalla Palma B; Bolzoni M; Todoerti K; Marcatti M; Schifano C; Bonomini S; Sammarelli G; Neri A; Ponzoni M; Aversa F; Giuliani N
    Int J Hematol; 2017 Jan; 105(1):104-108. PubMed ID: 27699576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corneal sub-basal neural damage pattern in multiple myeloma patients treated with bortezomib: an in vivo confocal study.
    Cocito F; Ricciardelli G; Mangiacavalli S; Pompa A; Pochintesta L; Ferretti V; Ceccuzzi R; Cazzola M; Bianchi PE; Corso A
    Leuk Lymphoma; 2015; 56(12):3440-1. PubMed ID: 25942384
    [No Abstract]   [Full Text] [Related]  

  • 20. Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma.
    Ocio EM; Dávila J; Caballero JC; Alonso S; de la Calle VG; García-Sanz R; Gazi L; Opio S; Jiménez M; San-Miguel JF; Mateos MV
    Haematologica; 2015 Jul; 100(7):e289-91. PubMed ID: 25795720
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.